Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document metrics and turnaround reporting while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
CMS-0057-F
The rule requires impacted payers to improve prior authorization decision timeframes and denial reasons, publish aggregated prior authorization metrics, and implement FHIR-based Prior Authorization and other interoperability APIs. The prior authorization API provisions addressed by the final rule exclude drugs. It changes prior authorization from a mainly plan-specific operational process into a federally time-bounded, reportable, and API-enabled workflow for impacted non-drug items and services. It also creates concrete buyer requirements for denial reasons, metrics lineage, and CRD, DTR, and PAS implementation.
CMS-0062-P
The proposal would extend many electronic prior authorization, decision-time, transparency, API, and reporting policies to drugs and would adopt or update FHIR-based standards and implementation specifications for prior authorization transactions. The proposals are not final policy. It could materially reduce the current boundary between medical-service and drug prior authorization regulation while changing standards, response times, and metrics. Buyers must plan for the possibility without treating proposed provisions as current obligations.
NCQA UM Accreditation
NCQA UM Accreditation evaluates organizations that make utilization decisions against a framework for objective, evidence-based, fair, and timely operations. Detailed standards cover clinical information, review processes, timeliness, appeals, and related controls. Accreditation changes the evaluation from feature presence to controlled operation. Technology can support evidence, timelines, reviewer qualification, and audit trails, but the organization—not the software—holds accreditation.
URAC Health UM Accreditation
URAC accredits health utilization-management organizations against standards intended to support effective, transparent, and efficient UM functions, including organizational accountability and consumer protections. URAC status can be relevant evidence about an organization's operating controls, but accreditation scope and expiration must be checked. A technology platform cannot inherit the accreditation of a service organization merely through integration.
CMS Part C UM Annual Data Submission
The collection requires Medicare Advantage organizations to submit information about internal coverage criteria used by the organization or delegated entities to process Part C prior authorizations, increasing oversight of policy and delegation practices. The submission creates a separate evidence requirement around the criteria used to make Part C authorization decisions. Buyers need policy provenance, delegation visibility, and extractable records in addition to transaction throughput.
Operating domains
Timeliness and access to care
Risk that authorization requirements, incomplete requests, review queues, handoffs, or unclear decisions delay or prevent clinically appropriate care beyond required or operationally acceptable timeframes.
Interoperability and transaction reliability
Risk that FHIR, X12, NCPDP, portal, fax, voice, identity, attachment, or legacy-system handoffs fail, lose meaning, duplicate work, or leave no reliable status and audit record.
Delegation, governance, and accountability
Risk that a health plan cannot demonstrate who owns policy, clinical review, decision authority, notices, appeals, metrics, accreditation, and oversight when work crosses internal teams and delegated organizations.
Denials, appeals, and member rights
Risk that adverse determinations lack specific, understandable reasons; appeal rights and peer review are hard to access; deadlines are missed; or later reversals cannot be analyzed without compromising member protections.
Transparency, metrics, and comparability
Risk that authorization counts, approval rates, denial rates, appeal outcomes, response times, and automation claims use incompatible populations, definitions, periods, or denominators and therefore mislead buyers or the public.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should metrics and turnaround reporting produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
First Medicare Part C UM annual data submission becomes due — Coverage-criteria provenance, delegation records, version control, and regulator-ready exports become more explicit enterprise requirements.
CMS releases CMS-0062-P for drug prior authorization and interoperability — Pharmacy ePA networks, payers, PBMs, EHRs, pharmacies, clearinghouses, and FHIR infrastructure providers need a scenario plan that preserves the distinction between current obligations and proposed changes.
Initial CMS-0057 prior-authorization metrics become due — Plan-level public disclosures create a new benchmarking input, but files require normalization by entity, population, period, request type, and denominator before comparison.
Humana targets fewer outpatient requirements and faster electronic decisions — Requirement removal, gold-carding, and faster-channel commitments change case volumes and workflow; each target needs post-effective-date validation by plan, service, and published metric.
Latitude Health announces an integrated GuidingCare workflow — The integration is an early example of specialized decision intelligence attaching to a core payer UM record without a full platform replacement.
Availity and Onyx launch a joint CMS-0057 platform — Health plans can source infrastructure and network reach together, but must still validate component ownership, conformance, production participation, and update responsibilities.